Pegunigalsidase alfa treatment for Fabry disease achieves safety, efficacy goals

Protalix BioTherapeutics Inc. and Chiesi Global Rare Diseases announced final results of the BRIGHT phase 3 clinical trial showing safety and efficacy of pegunigalsidase alfa as treatment for Fabry disease.
According to the press release, pegunigalsidase alfa (PRX-102) achieved safety, efficacy and pharmacokinetics.
In the multicenter, multinational open-label, switch-over BRIGHT phase 3 clinical trial, researchers examined 30 adults with Fabry disease who received an enzyme replacement therapy every 2 weeks for at least 3 years.
Researchers administered at least one dose of PRX-102 to patients

Protalix BioTherapeutics Inc. and Chiesi Global Rare Diseases announced final results of the BRIGHT phase 3 clinical trial showing safety and efficacy of pegunigalsidase alfa as treatment for Fabry disease.
According to the press release, pegunigalsidase alfa (PRX-102) achieved safety, efficacy and pharmacokinetics.
In the multicenter, multinational open-label, switch-over BRIGHT phase 3 clinical trial, researchers examined 30 adults with Fabry disease who received an enzyme replacement therapy every 2 weeks for at least 3 years.
Researchers administered at least one dose of PRX-102 to patients